EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

02.11.18

Pharma Patents Have Become Harder to Enforce, So IAM Together With the Patent Microcosm Sets Up Lobbying Events

Posted in America, Deception, Europe, Patents at 9:31 am by Dr. Roy Schestowitz

IAM: When “alternative facts” are up for sale (if one can afford them)

Battistelli and IAM

Summary: The difficulty associated with enforcing certain types of patents (more so after Mayo and § 101) means that litigious attitudes and reliance on law firms are decreasing; IAM strikes back with another one of its many lobbying events (designed to shape public opinion and influence key decision-makers)

THE concept of patents is pretty much universal, but not all patents are created equal. There are different sorts of patents (“families”) pertaining to or belonging to different domains. Speaking of them all as though they’re the same is the recipe for meaningless debates. Not all patents, for example, are a matter of life or death. Ethical aspects apply in some cases; sometimes pure economics.

“Not all patents, for example, are a matter of life or death.”As we discovered quite recently, EPO oppositions can crash companies. In other words, wrong decisions (or intentions) to grant can be truly harmful and pretty awful to workers. Things get pretty freaky when patents are being claimed on life itself. Forward Pharma lost 30% of its value (or valuation) in just one day at the end of January. This was due to an EPO decision. Yes, some sectors are over-reliant on patents; there’s no question about it. Here’s an example from two days ago: (in the UK)

Shares in Scancell Holdings PLC rose sharply on Friday morning as the company said its Moditope immunotherapy platform is to be granted a European patent.

Scancell shares were up 11% on Friday at 13.54 pence per share.

How good is this European Patent (EP)? Well, there’s lack of certainty under Battistelli, so Scancell Holdings PLC might be the next Forward Pharma (a one-day collapse).

“What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.”Pacific Biosciences is meanwhile attempting to ‘compete’ by causing embargo of its rival, Oxford Nanopore. We wrote about it some days ago and received plenty of comments from people involved in this matter. It’s yet another one of those ITC examples where patent litigation is geared towards embargoes and bankruptcies, not innovation. Here is what the face-saving press release said (striving to justify waste of shareholders’ money, spent on litigation). This campaign of patent litigation by Pacific Biosciences backfired pretty badly. “Pacific Bio down 2% premarket on ITC patent ruling,” Wall Street media stated shortly thereafter. To quote: “The ITC interpreted the term “single-molecule sequencing” as limited to sequencing-by-synthesis approaches, determining that Oxford’s sequencing approach is not “single-molecule sequencing.””

What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.

We have become increasingly supportive of the USPTO because it continues to deny patents on life and even software patents. PTAB helps and gravitates towards that. See the latest PTAB Life Sciences Report by John Cravero and Pharma Patents Blog writing about 35 U.S.C. § 101 rejections (not just based on Alice but also Mayo):

We’ve written previously about ex parte decisions of the Patent Trial and Appeal Board (PTAB) affirming patent eligibility rejections that seem to be inconsistent with the USPTO’s Subject Matter Eligibility Guidance. Apparently, applicants should be wary about appealing any rejection of a diagnostic method claim, because the PTAB may enter sua sponte patent eligibility rejections even if the examiner did not make a § 101 rejection.

Aside from § 101 there’s also 35 U.S.C. § 102. Hospira, based on this blog post, wins again. MedCo’s patent has been declared bogus as per § 102. To quote:

In the litigation, Hospira argued both (1) that the MedCo patents were invalid and (1) that Hospira’s proposed generic Angiomax drug would not infringe. The district court sided with MedCo on the first point (patents not invalid) but with Hospira on the second (patents not infringed). On appeal, the Federal Circuit has affirmed the non-infringement ruling but reversed on the on sale issue. The interesting portion is the on sale question.

Benjamin Anger and Jacob R. Rosenbaum wrote about it some days ago (very detailed).

“They get what they paid for. It’s pure lobbying/marketing.”As one can expect, the litigation ‘industry’ isn’t particularly happy about that. Many patents are being invalidated, which must be causing decrease in demand for patents and lawsuits (their main “offerings” or “services” or “products”).

There’s a “Pharma and Biotech IP Summit” being organised by IAM and as one can expect, the bill for this lobbying event is being footed by the main participants. “Finnegan is a Gold sponsor of IAM Magazine,” it says. There’s therefore a paid-for ‘talk’ (marketing). This not only helps Finnegan control the ‘debate’; it also keeps IAM on their ‘good side’ (maybe IAM will give Finnegan some more of these bogus ‘rewards’ or ‘endorsements’). “Jen Roscetti will present “The View from the United States” at @IAM_magazine’s #Pharma and #Biotech #IP Summit in London,” Finnegan wrote the other day. They get what they paid for. It’s pure lobbying/marketing.

“Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm.”With all honesty, more people ought to speak out about IAM’s “business model”, which involves collecting cash, pushing agenda (in the form of ‘news’ or staged ‘debates’), offering bogus ‘endorsements’, and issuing 'studies' for people like Battistelli (bolstering his lies). There’s nothing benign about it. IAM is effectively a think tank and even some less senior insiders must have realise it. Several of them left, only to be replaced by relatively young and inexperienced writers. Tim Lince, it should be noted, is still listed as a writer at IAM, but he wrote nothing this year and only 1 (one!) blog post last year. Many writers left and perhaps associating with people Battistelli (as we last noted last night) won’t save them but only cause further harm.

Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm. It’s like a propaganda platform facilitated by Joff Wild and his cohorts. He did the same for UPC (with cash from the EPO’s PR firm).

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

Leave a Comment

You must be logged in to post a comment.

What Else is New


  1. Links 19/2/2018: Linux 4.16 RC2, Nintendo Switch Now Full-fledged GNU/Linux

    Links for the day



  2. PTAB Continues to Invalidate a Lot of Software Patents and to Stop Patent Examiners From Issuing Them

    Erasure of software patents by the Patent Trial and Appeal Board (PTAB) carries on unabated in spite of attempts to cause controversy and disdain towards PTAB



  3. The Patent 'Industry' Likes to Mention Berkheimer and Aatrix to Give the Mere Impression of Section 101/Alice Weakness

    Contrary to what patent maximalists keep saying about Berkheimer and Aatrix (two decisions of the Federal Circuit from earlier this month, both dealing with Alice-type challenges), neither actually changed anything in any substantial way



  4. Makan Delrahim is Wrong; Patents Are a Major Antitrust Problem, Sometimes Disguised Using Trolls Somewhere Like the Eastern District of Texas

    Debates and open disagreements over the stance of the lobbyist who is the current United States Assistant Attorney General for the Antitrust Division



  5. Patent Trolls Watch: Microsoft-Connected Intellectual Ventures, Finjan, and Rumour of Technicolor-InterDigital Buyout

    Connections between various patent trolls and some patent troll statistics which have been circulated lately



  6. Software Patents Trickle in After § 101/Alice, But Courts Would Not Honour Them Anyway

    The dawn of § 101/Alice, which in principle eliminates almost every software patent, means that applicants find themselves having to utilise loopholes to fool examiners, but that's unlikely to impress judges (if they ever come to assessing these patents)



  7. In Aatrix v Green Shades the Court is Not Tolerating Software Patents But Merely Inquires/Wonders Whether the Patents at Hand Are Abstract

    Aatrix alleges patent infringement by Green Shades, but whether the patents at hand are abstract or not remains to be seen; this is not what patent maximalists claim it to be ("A Valentine for Software Patent Owners" or "valentine for patentee")



  8. An Indoctrinated Minority is Maintaining the Illusion That Patent Policy is to Blame for All or Most Problems of the United States

    The zealots who want to patent everything under the Sun and sue everyone under the Sun blame nations in the east (where the Sun rises) for all their misfortunes; this has reached somewhat ludicrous levels



  9. Berkheimer Decision is Still Being Spun by the Anti-Section 101/Alice Lobby

    12 days after Berkheimer v HP Inc. the patent maximalists continue to paint this decision as a game changer with regards to patent scope; the reality, however, is that this decision will soon be forgotten about and will have no substantial effect on either PTAB or Alice (because it's about neither of these)



  10. Academic Patent Immunity is Laughable and Academics Are Influenced by Corporate Money (for Steering Patent Agenda)

    Universities appear to have become battlegrounds in the war between practicing entities and a bunch of parasites who make a living out of litigation and patent bubbles



  11. UPC Optimism Languishes Even Among Paid UPC Propagandists Such as IAM

    Even voices which are attempting to give UPC momentum that it clearly lacks admit that things aren't looking well; the UK is not ratifying and Germany make take years to look into constitutional barriers



  12. Bejin Bieneman Props Up the Disgraced Randall Rader for Litigation Agenda

    Randall Rader keeps hanging out with the litigation 'industry' -- the very same 'industry' which he served in a closeted fashion when he was Chief Judge of the Federal Circuit (and vocal proponent of software patents, patent trolls and so on)



  13. With Stambler v Mastercard, Patent Maximalists Are Hoping to Prop Up Software Patents and Damage PTAB

    The patent 'industry' is hoping to persuade the highest US court to weaken the Patent Trial and Appeal Board (PTAB), for PTAB is making patent lawsuits a lot harder and raises the threshold for patent eligibility



  14. Apple Discovers That Its Patent Disputes Are a Losing Battle Which Only Lawyers Win (Profit From)

    By pouring a lot of money and energy into the 'litigation card' Apple lost focus and it's also losing some key cases, as its patents are simply not strong enough



  15. The Patent Microcosm Takes Berkheimer v HP Out of Context to Pretend PTAB Disregards Fact-Finding Process

    In view or in light of a recent decision (excerpt above), patent maximalists who are afraid of the Patent Trial and Appeal Board (PTAB) try to paint it as inherently unjust and uncaring for facts



  16. Microsoft Has Left RPX, But RPX Now Pays a Microsoft Patent Troll, Intellectual Ventures

    The patent/litigation arms race keeps getting a little more complicated, as the 'arms' are being passed around to new and old entities that do nothing but shake-downs



  17. UPC Has Done Nothing for Europe Except Destruction of the EPO and Imminent Layoffs Due to Lack of Applications and Lowered Value of European Patents

    The Unified Patent Court (UPC) is merely a distant dream or a fantasy for litigators; to everyone else the UPC lobby has done nothing but damage, including potentially irreparable damage to the European Patent Office, which is declining very sharply



  18. Links 17/2/2018: Mesa 17.3.4, Wine 3.2, Go 1.10

    Links for the day



  19. Patent Trolls Are Thwarted by Judges, But Patent Lawyers View Them as a 'Business' Opportunity

    Patent lawyers are salivating over the idea that trolls may be coming to their state/s; owing to courts and the Patent Trial and Appeal Board (PTAB) other trolls' software patents get invalidated



  20. Microsoft's Patent Moves: Dominion Harbor, Intellectual Ventures, Intellectual Discovery, NEC and Uber

    A look at some of the latest moves and twists, as patents change hands and there are still signs of Microsoft's 'hidden hand'



  21. Links 15/2/2018: GNOME 3.28 Beta, Rust 1.24

    Links for the day



  22. Bavarian State Parliament Has Upcoming Debate About Issues Which Can Thwart UPC for Good

    An upcoming debate about Battistelli's attacks on the EPO Boards of Appeal will open an old can of worms, which serves to show why UPC is a non-starter



  23. The EPO is Being Destroyed and There's Nothing Left to Replace It Except National Patent Offices

    It looks like Battistelli is setting up the European Patent Office (EPO) for mass layoffs; in fact, it looks as though he is so certain that the UPC will materialise that he obsesses over "validation" for mass litigation worldwide, departing from a "model office" that used to lead the world in terms of patent quality and workers' welfare/conditions



  24. IBM is Getting Desperate and Now Suing Microsoft Over Lost Staff, Not Just Suing Everyone Using Patents

    IBM's policy when it comes to patents, not to mention its alignment with patent extremists, gives room for thought if not deep concern; the company rapidly becomes more and more like a troll



  25. In Microsoft's Lawsuit Against Corel the Only Winner is the Lawyers

    The outcome of the old Microsoft v Corel lawsuit reaffirms a trend; companies with deep pockets harass their competitors, knowing that the legal bills are more cumbersome to the defendants; there's a similar example today in Cisco v Arista Networks



  26. The Latest Lies About Unitary Patent (UPC) and the EPO

    Lobbying defies facts; we are once again seeing some easily-debunked talking points from those who stand to benefit from the UPC and mass litigation



  27. Speech Deficit and No Freedom of Association at the EPO

    True information cannot be disseminated at the EPO and justice too is beyond elusive; this poses a threat to the EPO's future, not only to its already-damaged reputation



  28. No, Britain is Not Ratifying 'Unitary' Anything, But Team UPC Insinuates It Will (Desperate Effort to Affect Tomorrow's Outcome)

    Contrary to several misleading headlines from Bristows (in its blog and others'), the UPC isn't happening and isn't coming to the UK; it all amounts to lobbying (by setting false expectations)



  29. The EPO's Paid Promotion of Software Patents Gets Patent Maximalists All Excited and Emboldened

    The software patents advocacy from Battistelli (and his cohorts) isn't just a spit in the face of European Parliament but also the EPC; but patent scope seems to no longer exist or matter under his watch, as all he cares about is granting as many patents as possible, irrespective of real quality/legitimacy/merit



  30. Andrei Iancu Begins His USPTO Career While Former USPTO Director (and Now Paid Lobbyist) Keeps Meddling in Office Affairs

    The USPTO, which is supposed to be a government branch (loosely speaking) is being lobbied by former officials, who are now being paid by private corporations to help influence and shape policies; this damages the image of the Office and harms its independence from corporate influence


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts